Biotech & Pharmaceuticals Post-Brexit | Global Trade Magazine
  February 7th, 2019 | Written by

Biotech & Pharmaceuticals Post-Brexit

The Special Pharma Relationship

Sharelines

  • 98 percent of pharma execs say that Europe is an important market for their products.
  • The UK is second to Germany when it comes to the best countries for launching a new pharmaceutical product.
  • The UK is the preferred EU country for clinical trials.

Alacrita consulting released an infographic detailing insight from  leaders in the pharma and biotech industries and what their predictions are for a post-Brexit market. Survey results indicate what’s to come for leaders and industry players and how attitudes are predicting to change.

Some of the findings may come as a surprise for some, while other results can only be confirmed with time. For example, 98 percent of pharma execs say that Europe is an important market for their products. At the end of the day, the environment for clinical research, pharma companies and products could very well take a substantial shift.

The Special Pharma Relationship
Provided by Alacrita


Videos

Sponsored Content

Informative Articles from top Companies

Sponsored Content

%d bloggers like this: